GeoVax Labs (NASDAQ:GOVX – Get Free Report) and PTC Therapeutics (NASDAQ:PTCT – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.
Analyst Recommendations
This is a summary of recent ratings and target prices for GeoVax Labs and PTC Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GeoVax Labs | 1 | 1 | 1 | 0 | 2.00 |
| PTC Therapeutics | 1 | 3 | 10 | 1 | 2.73 |
GeoVax Labs presently has a consensus target price of $150.00, suggesting a potential upside of 104,795.10%. PTC Therapeutics has a consensus target price of $99.23, suggesting a potential upside of 52.59%. Given GeoVax Labs’ higher possible upside, analysts clearly believe GeoVax Labs is more favorable than PTC Therapeutics.
Institutional & Insider Ownership
6.1% of GeoVax Labs shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
GeoVax Labs has a beta of 3.85, meaning that its share price is 285% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500.
Profitability
This table compares GeoVax Labs and PTC Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GeoVax Labs | N/A | -743.64% | -394.74% |
| PTC Therapeutics | -9.17% | N/A | -0.10% |
Valuation & Earnings
This table compares GeoVax Labs and PTC Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GeoVax Labs | $2.49 million | 0.42 | -$21.47 million | ($11.34) | -0.01 |
| PTC Therapeutics | $1.73 billion | 3.14 | $682.64 million | ($1.40) | -46.45 |
PTC Therapeutics has higher revenue and earnings than GeoVax Labs. PTC Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.
Summary
PTC Therapeutics beats GeoVax Labs on 10 of the 15 factors compared between the two stocks.
About GeoVax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.
